Anti-tumor: IL-33 stimulates ILC2s to secrete CXCR2 ligands that bind to CXCR2-expressing tumor cells to induce tumor cell-specific apoptosis independently of adaptive immunity. The gene discussed is CXCR2; the disease is neoplasm.